SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Marksans Pharma - Quaterly Results

30 May 2024 Evaluate
The sales surged to Rs. 2251.96 millions, up 47.14% for the March 2024 quarter as against Rs. 1530.45 millions during the corresponding quarter previous year.Profit after tax for the quarter ended March 2024 reported a huge growth of 85.26% to Rs. 329.94  millions from Rs. 178.10 millions.The company reported a good operating profit of 460.99 millions compared to 270.12 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202403 202303 % Var 202403 202303 % Var 202403 202303 % Var
Sales 2251.96 1530.45 47.14 8532.73 6552.04 30.23 8532.73 6552.04 30.23
Other Income 121.94 43.03 183.38 620.73 604.82 2.63 620.73 604.82 2.63
PBIDT 460.99 270.12 70.66 2020.08 1523.85 32.56 2020.08 1523.85 32.56
Interest 2.28 6.58 -65.35 9.88 36.13 -72.65 9.88 36.13 -72.65
PBDT 458.71 263.54 74.06 2010.20 1487.72 35.12 2010.20 1487.72 35.12
Depreciation 74.72 35.09 112.94 291.28 167.37 74.03 291.28 167.37 74.03
PBT 383.99 228.45 68.08 1718.92 1320.35 30.19 1718.92 1320.35 30.19
TAX 54.05 50.35 7.35 381.34 291.69 30.73 381.34 291.69 30.73
Deferred Tax -31.08 -4.21 638.24 6.78 -1.71 -496.49 6.78 -1.71 -496.49
PAT 329.94 178.10 85.26 1337.58 1028.66 30.03 1337.58 1028.66 30.03
Equity 453.16 453.16 0.00 453.16 45316.00 -99.00 453.16 45316.00 -99.00
PBIDTM(%) 20.47 17.65 15.98 23.67 23.26 1.79 23.67 23.26 1.79

Marksans Pharma Share Price

180.20 -0.30 (-0.17%)
17-Apr-2026 11:10 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1679.60
Dr. Reddys Lab 1223.00
Cipla 1239.30
Zydus Lifesciences 945.45
Lupin 2318.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×